Covered recipient · General Payments record
MASOUD M AZIZAD
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$2,689.77
110 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,689.77 | 110 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $572.90 | 25 |
| Daiichi Sankyo Inc. | $496.51 | 19 |
| Regeneron Healthcare Solutions, Inc. | $420.16 | 11 |
| Lilly USA, LLC | $193.46 | 7 |
| Otsuka America Pharmaceutical, Inc. | $190.95 | 7 |
| Novartis Pharmaceuticals Corporation | $165.29 | 10 |
| Amgen Inc. | $148.88 | 9 |
| Abbott Laboratories | $108.57 | 5 |
| Bayer Healthcare Pharmaceuticals Inc. | $91.16 | 4 |
| GlaxoSmithKline, LLC. | $70.82 | 3 |
| PFIZER INC. | $52.24 | 2 |
| Impulse Dynamics (USA) Inc. | $36.25 | 1 |
| Exact Sciences Corporation | $33.57 | 2 |
| Phathom Pharmaceuticals, Inc. | $30.28 | 1 |
| Galderma Laboratories, L.P. | $23.87 | 1 |
| Novo Nordisk Inc | $21.80 | 1 |
| IRONWOOD PHARMACEUTICALS, INC | $17.75 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.31 | 1 |
Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MASOUD M AZIZAD
NPI 1033174826 · CMS profile ID 183370
Allopathic & Osteopathic Physicians / Internal Medicine
NORTHRIDGE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1033174826?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MASOUD M AZIZAD, NPI 1033174826, CMS profile ID 183370. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033174826?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MASOUD M AZIZAD, NPI 1033174826, CMS profile ID 183370. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033174826?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MASOUD M AZIZAD, NPI 1033174826, CMS profile ID 183370, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 110 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1033174826?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
110 matching records · $2,689.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 110.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.51 | 06/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258069 | CMS |
| Lilly USA, LLC | $32.82 | 06/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135181794 | CMS |
| Novartis Pharmaceuticals Corporation | $4.83 | 06/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086747801 | CMS |
| Amgen Inc. | $18.11 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115433743 | CMS |
| Novartis Pharmaceuticals Corporation | $10.73 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086747799 | CMS |
| ABBVIE INC. | $33.25 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258067 | CMS |
| Otsuka America Pharmaceutical, Inc. | $26.70 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118856735 | CMS |
| Novartis Pharmaceuticals Corporation | $5.02 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086747797 | CMS |
| Daiichi Sankyo Inc. | $27.12 | 05/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395669 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.24 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114002835 | CMS |
| Novartis Pharmaceuticals Corporation | $26.92 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086747791 | CMS |
| ABBVIE INC. | $12.73 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258065 | CMS |
| Exact Sciences Corporation | $14.84 | 05/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114582104 | CMS |
| Otsuka America Pharmaceutical, Inc. | $25.62 | 05/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118856733 | CMS |
| Lilly USA, LLC | $34.00 | 05/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135177733 | CMS |
| Abbott Laboratories | $24.47 | 05/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1124804884 | CMS |
| Daiichi Sankyo Inc. | $25.49 | 05/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395667 | CMS |
| PFIZER INC. | $26.65 | 05/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131358484 | CMS |
| GlaxoSmithKline, LLC. | $26.34 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116565726 | CMS |
| ABBVIE INC. | $31.78 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258063 | CMS |
| Otsuka America Pharmaceutical, Inc. | $22.73 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118856731 | CMS |
| ABBVIE INC. | $22.99 | 04/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258061 | CMS |
| Daiichi Sankyo Inc. | $29.06 | 04/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395661 | CMS |
| ABBVIE INC. | $20.88 | 04/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258059 | CMS |
| Novartis Pharmaceuticals Corporation | $32.47 | 04/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086747793 | CMS |
| ABBVIE INC. | $22.22 | 04/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258057 | CMS |
| Otsuka America Pharmaceutical, Inc. | $29.45 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118856729 | CMS |
| Daiichi Sankyo Inc. | $26.79 | 04/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395663 | CMS |
| Regeneron Healthcare Solutions, Inc. | $24.98 | 04/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114002833 | CMS |
| Amgen Inc. | $15.19 | 04/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117194548 | CMS |
| ABBVIE INC. | $25.49 | 03/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258055 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $23.05 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086108470 | CMS |
| Daiichi Sankyo Inc. | $27.62 | 03/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395653 | CMS |
| ABBVIE INC. | $14.86 | 03/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258053 | CMS |
| Amgen Inc. | $20.76 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117194544 | CMS |
| Amgen Inc. | $1.99 | 03/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117194546 | CMS |
| ABBVIE INC. | $12.84 | 03/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258051 | CMS |
| PFIZER INC. | $25.59 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131130600 | CMS |
| Daiichi Sankyo Inc. | $26.93 | 03/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395655 | CMS |
| Lilly USA, LLC | $31.16 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135203158 | CMS |
| ABBVIE INC. | $19.19 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258049 | CMS |
| Novartis Pharmaceuticals Corporation | $32.26 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086747789 | CMS |
| Daiichi Sankyo Inc. | $25.19 | 02/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089395665 | CMS |
| Impulse Dynamics (USA) Inc. | $36.25 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1100421963 | CMS |
| Regeneron Healthcare Solutions, Inc. | $25.26 | 02/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114002831 | CMS |
| Regeneron Healthcare Solutions, Inc. | $27.57 | 02/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114002829 | CMS |
| IRONWOOD PHARMACEUTICALS, INC | $17.75 | 02/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1153735292 | CMS |
| ABBVIE INC. | $18.09 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103258047 | CMS |
| Otsuka America Pharmaceutical, Inc. | $29.59 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118856727 | CMS |
| Amgen Inc. | $20.28 | 01/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117194542 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,501,735.50 | 276 |
| PY2024 | Recipient | $1,876.00 | 1 |
| PY2024 | Principal investigator | $2,072,364.33 | 91 |
| PY2023 | Recipient | $4,147.58 | 1 |
| PY2023 | Principal investigator | $1,852,343.80 | 53 |
| PY2022 | Recipient | $9,644.00 | 1 |
| PY2022 | Principal investigator | $2,485,525.48 | 54 |
| PY2021 | Recipient | $2,995.53 | 1 |
| PY2021 | Principal investigator | $9,996,231.35 | 100 |
| PY2020 | Principal investigator | $2,408,536.67 | 140 |
| PY2019 | Principal investigator | $777,399.83 | 96 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
276 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $20,020.56 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc. | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1232929585 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $274.40 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc. | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1232929587 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $0.58 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc. | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine wi | No dispute reported | 06/30/2026 | 1232933138 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $159.25 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc. | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA-1273 SARS-CoV-2 Vaccines Where the First Dose of Each Vaccine Are Given Concomitantly in Boys and Girls 9 to 11 Years of Age | No dispute reported | 06/30/2026 | 1232933210 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $55,309.34 | 12/31/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc. | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent | No dispute reported | 06/30/2026 | 1232933618 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,290.00 | 12/17/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $547.50 | 12/17/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.14 | 12/17/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785091 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,044.60 | 12/16/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817918 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,047.00 | 12/16/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817920 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,477.00 | 12/15/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174207 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $79,337.83 | 12/15/2025 | Non-covered Recipient Entity Valley Clinical Trials Inc. | A Phase 3, International, Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy, Immunogenicity, and Safety of the 9vHPV Vaccine, a Multivalent L1 Virus-like Particle Vaccine, in the prevention of oral persistent | No dispute reported | 06/30/2026 | 1232933616 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,881.00 | 12/12/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174686 |
| Principal investigator 1 | Janssen Research & Development, LLC | $200.00 | 12/12/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346355 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $627.20 | 12/10/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513667 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $73,488.66 | 12/10/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc. | A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression | No dispute reported | 06/30/2026 | 1232929583 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,000.00 | 12/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215513610 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $20,895.00 | 12/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215513613 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,750.00 | 12/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215513617 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,377.00 | 12/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215513623 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $266.00 | 12/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513655 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $119.00 | 12/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513659 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $15,382.60 | 12/03/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185537151 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $579.60 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785077 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,696.00 | 11/21/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,688.00 | 11/19/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174662 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $23,219.10 | 11/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817914 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,826.67 | 11/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817916 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513646 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $60.00 | 11/12/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513650 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010180 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,190.00 | 11/07/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174551 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $266.00 | 11/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513662 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,246.00 | 11/03/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174202 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785065 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 10/29/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817908 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,785.60 | 10/29/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817910 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 10/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $442.20 | 10/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 10/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 10/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785087 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 10/23/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817906 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $902.65 | 10/22/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513634 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,859.00 | 10/22/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174489 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,899.00 | 10/20/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817912 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,212.40 | 10/17/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513631 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,743.00 | 10/17/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174711 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $23,125.00 | 10/15/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC. | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185537149 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7.25 | 10/13/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346305 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27.00 | 10/13/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346312 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7.79 | 10/13/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346326 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2.03 | 10/13/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346334 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,350.00 | 10/09/2025 | Non-covered Recipient Entity Vly Clnc Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174246 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785049 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $266.00 | 09/26/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513507 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $180.00 | 09/26/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513512 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.92 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785037 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,511.00 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817896 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $334.00 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817898 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817900 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817902 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,344.00 | 09/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817904 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,743.00 | 09/24/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174403 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 09/22/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817894 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,274.50 | 09/19/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817892 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,161.00 | 09/19/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174646 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,212.00 | 09/19/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174744 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 09/17/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513516 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,691.70 | 09/17/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513520 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,980.25 | 09/17/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513529 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 09/11/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817888 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/11/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817890 |
| Principal investigator 1 | Amgen Inc. | $12,341.64 | 09/09/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS, INC. | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity | No dispute reported | 06/30/2026 | 1246651148 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785025 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,165.00 | 08/29/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346319 |
| Principal investigator 1 | ModernaTX, Inc. | $79.04 | 08/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010200 |
| Principal investigator 1 | Janssen Research & Development, LLC | $201.00 | 08/25/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174637 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,900.00 | 08/25/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174678 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,695.00 | 08/13/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174543 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,726.90 | 08/08/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817886 |
| Principal investigator 1 | Amgen Inc. | $158,102.50 | 08/01/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS, INC. | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246651144 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $547.50 | 07/28/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $552.75 | 07/28/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $37.50 | 07/28/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 07/28/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785033 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,463.00 | 07/23/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174337 |
| Principal investigator 1 | Janssen Research & Development, LLC | $674.00 | 07/23/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174751 |
| Principal investigator 1 | ModernaTX, Inc. | $830.13 | 07/23/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $792.00 | 07/21/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346364 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,212.40 | 07/16/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785013 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220785021 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $35,856.00 | 06/26/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817884 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,795.00 | 06/26/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174417 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $456.00 | 06/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817880 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $216.00 | 06/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817882 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $46.64 | 06/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784987 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,872.00 | 06/23/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174669 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,139.00 | 06/20/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174496 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,175.00 | 06/20/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174796 |
| Principal investigator 1 | ModernaTX, Inc. | $22,188.98 | 06/18/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010192 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,506.00 | 06/13/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346349 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,634.00 | 06/12/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346342 |
| Principal investigator 1 | ModernaTX, Inc. | $4,149.60 | 06/04/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010174 |
| Principal investigator 1 | ModernaTX, Inc. | $830.13 | 06/04/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010176 |
| Principal investigator 1 | ModernaTX, Inc. | $296.40 | 06/04/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784973 |
| Principal investigator 1 | ModernaTX, Inc. | $17,532.00 | 05/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010188 |
| Principal investigator 1 | ModernaTX, Inc. | $42,703.32 | 05/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010198 |
| Principal investigator 1 | ModernaTX, Inc. | $16,697.20 | 05/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.32 | 05/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $949.00 | 05/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $530.64 | 05/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784981 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.80 | 05/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784983 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,492.00 | 05/21/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174352 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $76.00 | 05/15/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817878 |
| Principal investigator 1 | ModernaTX, Inc. | $4,980.78 | 05/15/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010196 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16,289.10 | 05/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817876 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $120.00 | 05/07/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513468 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 05/07/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513475 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784961 |
| Principal investigator 1 | Eli Lilly and Company | $192.34 | 04/30/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187890994 |
| Principal investigator 1 | ModernaTX, Inc. | $6,698.56 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010186 |
| Principal investigator 1 | ModernaTX, Inc. | $19,266.00 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010190 |
| Principal investigator 1 | ModernaTX, Inc. | $26,298.00 | 04/28/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010224 |
| Principal investigator 1 | Amgen Inc. | $23,327.23 | 04/23/2025 | Non-covered Recipient Entity FLOURISH RESEARCH | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) | No dispute reported | 06/30/2026 | 1246641439 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $442.20 | 04/23/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784975 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,983.00 | 04/23/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174265 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $5,918.65 | 04/18/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513487 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,048.64 | 04/17/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and | No dispute reported | 06/30/2026 | 1190313591 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $500.00 | 04/16/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513452 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 04/16/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513457 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,147.10 | 04/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817874 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,000.00 | 04/11/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513461 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,775.85 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $552.75 | 03/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.00 | 03/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784933 |
| Principal investigator 1 | ModernaTX, Inc. | $26,298.00 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010212 |
| Principal investigator 1 | ModernaTX, Inc. | $17,606.16 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010214 |
| Principal investigator 1 | ModernaTX, Inc. | $15,490.42 | 03/24/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010220 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $119.00 | 03/21/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513379 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,313.00 | 03/21/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174513 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,318.00 | 03/17/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174695 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $38,144.70 | 03/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817872 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $500.00 | 03/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817868 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $800.00 | 03/13/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817870 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,409.70 | 03/12/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513394 |
| Principal investigator 1 | Janssen Research & Development, LLC | $593.97 | 03/07/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175346297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784913 |
| Principal investigator 1 | ModernaTX, Inc. | $28,468.88 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010178 |
| Principal investigator 1 | ModernaTX, Inc. | $19,562.40 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010184 |
| Principal investigator 1 | ModernaTX, Inc. | $18,993.00 | 02/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010206 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 02/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 02/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $663.30 | 02/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 02/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.70 | 02/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $13.80 | 02/25/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784929 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $266.00 | 02/21/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513337 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $471.80 | 02/21/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513366 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $120.00 | 02/19/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513313 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $119.00 | 02/19/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513323 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,500.00 | 02/19/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513346 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,731.00 | 02/19/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174466 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $60.00 | 02/14/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513329 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,158.20 | 02/14/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817852 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $180.00 | 02/07/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513349 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,547.00 | 02/07/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513354 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $120.00 | 02/07/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,316.00 | 02/07/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174894 |
| Principal investigator 1 | Eli Lilly and Company | $29,386.00 | 02/04/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187893534 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $3,236.60 | 02/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513398 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,962.90 | 02/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513403 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,938.40 | 02/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513407 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,873.20 | 02/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513411 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $8,058.05 | 02/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513415 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $363.70 | 02/03/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784901 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.00 | 01/31/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817854 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.00 | 01/31/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817856 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $76.00 | 01/31/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817858 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8.00 | 01/31/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817860 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.00 | 01/31/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817862 |
| Principal investigator 1 | Eli Lilly and Company | $195.00 | 01/31/2025 | Non-covered Recipient Entity MEHRDAD KEVIN ARIANI MD | A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1187884938 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $922.20 | 01/29/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817866 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,781.50 | 01/28/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817864 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $876.00 | 01/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.36 | 01/27/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784917 |
| Principal investigator 1 | ModernaTX, Inc. | $8,373.20 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010202 |
| Principal investigator 1 | ModernaTX, Inc. | $20,629.44 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010208 |
| Principal investigator 1 | ModernaTX, Inc. | $26,298.00 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010216 |
| Principal investigator 1 | ModernaTX, Inc. | $54,137.20 | 01/27/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010222 |
| Principal investigator 1 | Janssen Research & Development, LLC | $897.00 | 01/22/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | No dispute reported | 06/30/2026 | 1175174456 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,902.00 | 01/22/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174611 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $22,346.10 | 01/20/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817848 |
| Principal investigator 1 | ModernaTX, Inc. | $1,092.00 | 01/17/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010194 |
| Principal investigator 1 | ModernaTX, Inc. | $14,112.21 | 01/17/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253010210 |
| Principal investigator 1 | Eli Lilly and Company | $749.05 | 01/09/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187890988 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $1,746.20 | 01/08/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513386 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $70.00 | 01/08/2025 | Non-covered Recipient Entity Valley Clinical Trials, Inc - Northridge - Flourish - PPDS | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) | No dispute reported | 06/30/2026 | 1215513390 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,114.80 | 01/07/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220817850 |
| Principal investigator 1 | Eli Lilly and Company | $20,814.00 | 01/07/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS INC | A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | No dispute reported | 06/30/2026 | 1187891614 |
| Principal investigator 1 | Janssen Research & Development, LLC | $157.00 | 01/06/2025 | Non-covered Recipient Entity Vly Clinic Trials | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175174314 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $5,000.00 | 01/03/2025 | Non-covered Recipient Entity VALLEY CLINICAL TRIALS | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185537153 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Valley Clinical Trials | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220784935 |